Design, synthesis, and biological evaluation of a series of benzo[ de ][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors

Na Ye, Chuan Huizi Chen, Tiantian Chen, Zilan Song, Jin Xue He, Xia Juan Huan, Shan Shan Song, Qiufeng Liu, Yi Chen, Jian Ding, Yechun Xu, Ze Hong Miao, Ao Zhang

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors. The initial effort led to the first-generation PARP1 inhibitor 26 bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity (0.31 nM) but only moderate potency in the cell. Further effort generated the second-generation lead 41, showing high potency against both the PARP1 enzyme and BRCA-deficient cells, especially for the BRCA1-deficient MDA-MB-436 cells (CC50 <0.26 nM). Mechanistic studies revealed that the new PARP1 inhibitors significantly inhibited H 2O2-triggered PARylation in SKOV3 cells, induced cellular accumulation of DNA double-strand breaks, and impaired cell-cycle progression in BRCA2-deficient cells. Significant potentiation on the cytotoxicity of Temozolomide was also observed. The unique structural character and exceptionally high potency of 41 made it stand out as a promising drug candidate worthy for further evaluation.

Original languageEnglish (US)
Pages (from-to)2885-2903
Number of pages19
JournalJournal of Medicinal Chemistry
Volume56
Issue number7
DOIs
StatePublished - Apr 11 2013
Externally publishedYes

Fingerprint

temozolomide
Double-Stranded DNA Breaks
Cell Cycle
Enzymes
Pharmaceutical Preparations
Lead

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Design, synthesis, and biological evaluation of a series of benzo[ de ][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors. / Ye, Na; Chen, Chuan Huizi; Chen, Tiantian; Song, Zilan; He, Jin Xue; Huan, Xia Juan; Song, Shan Shan; Liu, Qiufeng; Chen, Yi; Ding, Jian; Xu, Yechun; Miao, Ze Hong; Zhang, Ao.

In: Journal of Medicinal Chemistry, Vol. 56, No. 7, 11.04.2013, p. 2885-2903.

Research output: Contribution to journalArticle

Ye, N, Chen, CH, Chen, T, Song, Z, He, JX, Huan, XJ, Song, SS, Liu, Q, Chen, Y, Ding, J, Xu, Y, Miao, ZH & Zhang, A 2013, 'Design, synthesis, and biological evaluation of a series of benzo[ de ][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors', Journal of Medicinal Chemistry, vol. 56, no. 7, pp. 2885-2903. https://doi.org/10.1021/jm301825t
Ye, Na ; Chen, Chuan Huizi ; Chen, Tiantian ; Song, Zilan ; He, Jin Xue ; Huan, Xia Juan ; Song, Shan Shan ; Liu, Qiufeng ; Chen, Yi ; Ding, Jian ; Xu, Yechun ; Miao, Ze Hong ; Zhang, Ao. / Design, synthesis, and biological evaluation of a series of benzo[ de ][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 7. pp. 2885-2903.
@article{ced7bd1aaed244cb8ed72672081941cd,
title = "Design, synthesis, and biological evaluation of a series of benzo[ de ][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors",
abstract = "A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors. The initial effort led to the first-generation PARP1 inhibitor 26 bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity (0.31 nM) but only moderate potency in the cell. Further effort generated the second-generation lead 41, showing high potency against both the PARP1 enzyme and BRCA-deficient cells, especially for the BRCA1-deficient MDA-MB-436 cells (CC50 <0.26 nM). Mechanistic studies revealed that the new PARP1 inhibitors significantly inhibited H 2O2-triggered PARylation in SKOV3 cells, induced cellular accumulation of DNA double-strand breaks, and impaired cell-cycle progression in BRCA2-deficient cells. Significant potentiation on the cytotoxicity of Temozolomide was also observed. The unique structural character and exceptionally high potency of 41 made it stand out as a promising drug candidate worthy for further evaluation.",
author = "Na Ye and Chen, {Chuan Huizi} and Tiantian Chen and Zilan Song and He, {Jin Xue} and Huan, {Xia Juan} and Song, {Shan Shan} and Qiufeng Liu and Yi Chen and Jian Ding and Yechun Xu and Miao, {Ze Hong} and Ao Zhang",
year = "2013",
month = "4",
day = "11",
doi = "10.1021/jm301825t",
language = "English (US)",
volume = "56",
pages = "2885--2903",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Design, synthesis, and biological evaluation of a series of benzo[ de ][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors

AU - Ye, Na

AU - Chen, Chuan Huizi

AU - Chen, Tiantian

AU - Song, Zilan

AU - He, Jin Xue

AU - Huan, Xia Juan

AU - Song, Shan Shan

AU - Liu, Qiufeng

AU - Chen, Yi

AU - Ding, Jian

AU - Xu, Yechun

AU - Miao, Ze Hong

AU - Zhang, Ao

PY - 2013/4/11

Y1 - 2013/4/11

N2 - A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors. The initial effort led to the first-generation PARP1 inhibitor 26 bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity (0.31 nM) but only moderate potency in the cell. Further effort generated the second-generation lead 41, showing high potency against both the PARP1 enzyme and BRCA-deficient cells, especially for the BRCA1-deficient MDA-MB-436 cells (CC50 <0.26 nM). Mechanistic studies revealed that the new PARP1 inhibitors significantly inhibited H 2O2-triggered PARylation in SKOV3 cells, induced cellular accumulation of DNA double-strand breaks, and impaired cell-cycle progression in BRCA2-deficient cells. Significant potentiation on the cytotoxicity of Temozolomide was also observed. The unique structural character and exceptionally high potency of 41 made it stand out as a promising drug candidate worthy for further evaluation.

AB - A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors. The initial effort led to the first-generation PARP1 inhibitor 26 bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity (0.31 nM) but only moderate potency in the cell. Further effort generated the second-generation lead 41, showing high potency against both the PARP1 enzyme and BRCA-deficient cells, especially for the BRCA1-deficient MDA-MB-436 cells (CC50 <0.26 nM). Mechanistic studies revealed that the new PARP1 inhibitors significantly inhibited H 2O2-triggered PARylation in SKOV3 cells, induced cellular accumulation of DNA double-strand breaks, and impaired cell-cycle progression in BRCA2-deficient cells. Significant potentiation on the cytotoxicity of Temozolomide was also observed. The unique structural character and exceptionally high potency of 41 made it stand out as a promising drug candidate worthy for further evaluation.

UR - http://www.scopus.com/inward/record.url?scp=84876257495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876257495&partnerID=8YFLogxK

U2 - 10.1021/jm301825t

DO - 10.1021/jm301825t

M3 - Article

VL - 56

SP - 2885

EP - 2903

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -